The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - ABBVIE; AstraZeneca; Blueprint Medicines; BOEHRINGER INGELHEIM; BRISTOL-MYERS SQUIBB; Guardant Health; JANSSEN; LILLY; MERCK KGaA; MERCK SHARP & DOHME; NOVARTIS; PFIZER; Roche; SAMSUNG; TAKEDA
Speakers' Bureau - AstraZeneca; BRISTOL-MYERS SQUIBB; LILLY; MEDSCAPE; Merck Sharp & Dohme; NOVARTIS; PFIZER; prIME ONCOLOGY; ROCHE; TAKEDA; touchIME
Research Funding - Grant for Oncology Innovation; Merck
Other Relationship - GRÍFOLS
Nazartinib (EGF816) in patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results.
 
Daniel Shao-Weng Tan
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Loxo; Merck; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Natasha B. Leighl
Consulting or Advisory Role - Xcovery
Research Funding - Array BioPharma (Inst); Guardant Health (Inst); Novartis (Inst); Roche Canada (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Nektar; Roche
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca (Inst); Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; G1 Therapeutics; Hansoh; Incyte; Lilly; Merck Serono; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Takeda; Yuhan
Travel, Accommodations, Expenses - Pfizer
 
Gregory J. Riely
Research Funding - GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
Other Relationship - Pfizer; Roche/Genentech; Takeda
 
Lecia V. Sequist
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Genentech/Roche; Janssen Oncology; Merrimack
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Genentech (Inst); Guardant Health (Inst); Incyte (Inst); Johnson & Johnson (Inst); Loxo (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst)
 
Ryo Toyozawa
Honoraria - Bristol-Myers Squibb; MSD; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Daiichi Sankyo (Inst); Pfizer (Inst); Takeda (Inst)
 
Juergen Wolf
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Ignyta; Janssen; Lilly; Loxo/Lilly; MSD Oncology; Novartis; Pfizer; Roche; Takeda
Research Funding - Bristol-Myers Squibb; Janssen; Novartis; Pfizer
 
Enriqueta Felip
No Relationships to Disclose
 
Sang-We Kim
No Relationships to Disclose
 
Santiago Ponce Aix
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche
Travel, Accommodations, Expenses - AstraZeneca; Merck; Roche
 
Egbert F. Smit
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck KGaA (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Novartis (Inst); Regeneron (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Toyoaki Hida
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Clovis Oncology; Kissei Pharmaceutical; Lilly; MSD; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Ignyta (Inst); Janssen (Inst); Kissei Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Servier (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Christian Grohé
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD Oncology; Novartis; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD Oncology
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Roche
 
Samson Ghebremariam
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Novartis
 
Leslie O’Sullivan-Djentuh
Employment - Novartis
 
Riccardo Belli
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Monica Giovannini
Employment - Novartis
Leadership - AstraZeneca; AstraZeneca (I); Bluebird Bio; Celgene; Celgene (I); Novartis; Novartis (I)
Stock and Other Ownership Interests - AstraZeneca; Bluebird Bio; Celgene; Celgene (I); Novartis; Novartis (I)
 
Dong-Wan Kim
Research Funding - Alpha Biopharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Hanmi (Inst); Janssen (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo